Nanotechnology approaches for personalized treatment of multidrug resistant cancers

https://doi.org/10.1016/j.addr.2013.09.017Get rights and content
Under a Creative Commons license
open access

Abstract

The efficacy of chemotherapy is substantially limited by the resistance of cancer cells to anticancer drugs that fluctuates significantly in different patients. Under identical chemotherapeutic protocols, some patients may receive relatively ineffective doses of anticancer agents while other individuals obtain excessive amounts of drugs that induce severe adverse side effects on healthy tissues. The current review is focused on an individualized selection of drugs and targets to suppress multidrug resistance. Such selection is based on the molecular characteristics of a tumor from an individual patient that can potentially improve the treatment outcome and bring us closer to an era of personalized medicine.

Abbreviations

ABC
adenosine triphosphate (ATP)-binding cassette
ASO
antisense oligonucleotides
CPT
camptothecin
DBD
drug-binding domain
DDS
drug delivery system
DOX
doxorubicin
EPR
enhanced permeability and retention effect
IC50 dose
a dose that kills 50% of cells
LHRH
luteinizing hormone-release hormone
NBD
nucleotide-binding domain
NLC
nanostructured lipid carriers
PAMAM
poly(amido amine)
siRNA
small interfering RNA
SNP
single-nucleotide polymorphism
TMD
transmembrane domain
TPADDS
targeted proapoptotic drug delivery system

Keywords

Passive and active targeting
Drug delivery system
Pump and nonpump resistance
Antibody
siRNA
Antisense oligonucleotides
Peptides
Cancer stem cells
LHRH
CD44

Cited by (0)

This review is part of the Advanced Drug Delivery Reviews theme issue on “Nanotechnology and drug resistance”.